IP Library Granted Patent US 10,064,404
Granted Patent B2
US 10,064,404 · App. 15/316,677 · Granted Sep 4, 2018

Stabilization of thrombocytes at ambient temperatures

Inventors: Rolf Muller (Del Mar, CA); Joel Desharnais (La Mesa, CA); Steven P. Wilkinson (Poway, CA); Victoria Arendt (San Diego, CA); Paul Diaz (Riverside, CA)
Assignee: BIOMATRICA, INC.
A01N1/0226
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,404
App. No.
15/316,677
Granted
Sep 4, 2018
Kind
B2
Abstract

Provided herein are formulations and methods for the stabilization of one or more thrombocytes at ambient temperatures. Also provided are formulations and methods for the stabilization of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures. Further provided are articles of manufacture and kits and methods for substantially stable storage of one or more thrombocyte at ambient temperatures.

Claims (8)

1. A composition for substantially stable storage of one or more thrombocytes at ambient temperature, comprising a halogenated disaccharide derivative and an anticoagulant,

wherein the halogenated disaccharide derivative is present at 0.1-50 μM, and

wherein the thrombocytes are stabilized for a period of at least 6 hours.

2. The composition of claim 1 , wherein the composition further comprises a buffer.

3. The composition of claim 1 , wherein the anticoagulant is hirudin.

4. The composition of claim 1 , wherein the halogenated disaccharide derivative is selected from the group consisting of sucralose (1,6,-dichloro-1,6,dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6,-dichloro-1,6,dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, 1,6,-dichloro-1,6,dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and combinations thereof.

5. The composition of claim 1 , wherein the composition consists essentially of hirudin and sucralose (1,6,-dichloro-1,6,dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside).

6. The composition of claim 1 , wherein the anticoagulant is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), hirudin, heparin, and sodium citrate.

Assignments (2)
SECURITY INTEREST Recorded Jun 18, 2018
From: BIOMATRICA, INC.
To: EXACT SCIENCES CORPORATION
Reel/Frame 046120/0869 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2017
From: MULLER, ROLF; DESHARNAIS, JOEL; WILKINSON, STEVEN P.; ARENDT, VICTORIA; DIAZ, PAUL
To: BIOMATRICA, INC.
Reel/Frame 043628/0361 →
Continuity (2)
Provisional Application 62010151 · Jun 10, 2014
Related Publication 20170196220A1 · Jul 13, 2017